Background: Thrombolysis with tissue plasminogen activator (tPA) remains the only approved drug therapy for acute ischemic stroke. However, delayed tPA treatment is associated with an increased risk ...

In this retrospective cohort study, Bruce et al. sought to investigate possible associations between dementia-free stroke survivors after an intracranial hemorrhage and the risk of a first-ever ...

A new study has found that the clot-dissolving drug alteplase can significantly improve stroke recovery even when given up to 24 hours after a stroke begins. The results, presented at the American ...

Tissue plasminogen activator (TPA) may be given, but it must be administered within the first few hours ... These types of changes may be suggested to help control the effects of diabetes. The two ...

Strokes are a major cause of death and disability and the third leading cause of death in western society. It is estimated 3% ...

The study enrolled 372 stroke patients in a multicenter, prospective, randomized trial at 26 stroke centers in China. The patient's average age was 72 years, and 43% were women.

In new guidance, NICE has cleared NHS use of Boehringer Ingelheim's clot-busting therapy Metalyse as a treatment for acute ischaemic stroke in adults. The healthcare cost-effectiveness watchdog ...

Contribute to Golu9174552662/sheet development by creating an account on GitHub.